Pathology and Lab Medicine

Episodes 1-15 of 62

• 

  RestartResume

  Guideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor

  MinuteCE®

  Guideline-recommended treatment options for patients with CLL/SLL and MCL that have progressed following a covalent BTK inhibitor

  • 

    

    Seema A. Bhat, MD

    Peer

  • 

    

    Jeremy S. Abramson, MD, MMSc

    Peer

  0.50 program credits

• 

  RestartResume

  Clinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies

  MinuteCE®

  Clinical trial evidence that drives current guidelines for patients with CLL/SLL and MCL receiving third-line therapies

  • 

    

    Seema A. Bhat, MD

    Peer

  • 

    

    Jeremy S. Abramson, MD, MMSc

    Peer

  0.50 program credits

• 

  RestartResume

  Incorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy

  MinuteCE®

  Incorporating guideline-concordant care for patients with CLL/SLL relapsing after 2 prior lines of therapy

  • 

    

    Seema A. Bhat, MD

    Peer

  • 

    

    Jeremy S. Abramson, MD, MMSc

    Peer

  0.50 program credits

• 

  RestartResume

  Emerging data with potentially guideline-changing implications in CLL/SLL and MCL

  MinuteCE®

  Emerging data with potentially guideline-changing implications in CLL/SLL and MCL

  • 

    

    Seema A. Bhat, MD

    Peer

  • 

    

    Jeremy S. Abramson, MD, MMSc

    Peer

  0.50 program credits

• 

  MinuteCE®

  Innovations in Oncology Learning Center From Guidelines to Practice: Genitourinary Cancers

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Wenxin Xu, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 credits 10 episodes

• 

  RestartResume

  Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

  MinuteCE®

  Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Wenxin Xu, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  MinuteCE®

  Clinical evidence driving guideline recommendations for monotherapy in the second-line or later setting in metastatic urothelial cancer

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  MinuteCE®

  Incorporation of guideline-concordant care for first-line treatment of a patient with metastatic urothelial carcinoma

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer

  MinuteCE®

  Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer

  • 

    

    Wenxin Xu, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  MinuteCE®

  Incorporation of guideline recommendations into the frontline care of a patient with mCRPC who is naïve to both docetaxel and novel hormone therapy

  • 

    

    Wenxin Xu, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  MinuteCE®

  Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma

  • 

    

    Wenxin Xu, MD

    Peer

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  MinuteCE®

  Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Wenxin Xu, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Emerging targeted therapy combination strategies in genitourinary malignancies

  MinuteCE®

  Emerging targeted therapy combination strategies in genitourinary malignancies

  • 

    

    Ignacio Duran, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Emerging immunotherapy combination strategies in genitourinary malignancies

  MinuteCE®

  Emerging immunotherapy combination strategies in genitourinary malignancies

  • 

    

    Sandy Srinivas, MD

    Peer

  1.25 program credits

• 

  RestartResume

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  MinuteCE®

  Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies

  • 

    

    Ignacio Duran, MD

    Peer

  • 

    

    Wenxin Xu, MD

    Peer

  1.25 program credits

• 1
• 2
• 3
• 4
• 5
• Next